Rosanna Sutherby, Pharm.D.

Plans call for 12 sites and two advisory boards.

Sarepta Therapeutics and Roche are competing with Pfizer to develop the first gene replacement therapy for Duchenne muscular dystrophy. Sarepta and Roche are ahead after the FDA put a clinical hold on Pfizer’s product.

The diagnostic window is a common concept in oncology. The researchers applied it to ulcerative colitis and other conditions.

The researchers suggest more research, including head-to-head trials, to sort out the relative merits of the treatments for ulcerative colitis.

If Morphic Therapeutic's ulcerative colitis drug is approved by the FDA it would likely compete with Entyvio. Pfizer's etrasimod may also enter the fray.

Antibiotic treatment in childhood may disrupt the microbiome and have long-term consequences.

Patients treated with the gut-selective monoclonal antibody were three times more likely to achieve remission of inflammation of ileal pouch-anal anastomosis, an alternative to a life-long colostomy bag after colectomy.

The VIDAMS trial compared daily of 5,000 international units (IUs) to 600 IUs.

The FDA decision is based on increased liver enzyme levels seen in two participants during the phase 3 studies.

Neurologists may feel ill-equipped to manage or identify sexual problems of multiple sclerosis patients, wrote the authors, but it's important they ask patients about sexual function and satisfaction.

Three ADCs are in late-stage trials as treatments for patients with non-small cell lung cancer.

Eli Lilly’s mirikizumab and Pfizer’s etrasimod are expected to be approved by the FDA this year.

Researchers caution, though, that their findings should not be construed as an endorsement of liberal use of opioids by new mothers.

But transcutaneous electrical nerve stimulation (TENS) edged out interferential current therapy (IFT) on several measures.

The Multiple Sclerosis International Federation has applied to have Rituxan, Mavenclad and Copaxone added to the World Health Organization’s list of essential medications.

By activating the farnesoid X receptor, psyllium may have anti-inflammatory effects.

Authors of a study published in Gastroenterology say results show that an artificial intelligence-based, computer-aided model accurately differentiates disease remission from inflammation.

The newly approved treatment for relapsing multiple sclerosis is priced at $59,000 per year. The Institute for Clinical and Economic Review said it should be priced at between $16,000 and $34,900 to meet commonly accepted thresholds for cost effectiveness.

Research stalled for decades after deaths in a 1960s trial. Now Pfizer and other companies are reporting results for a vaccine against respiratory syncytial virus infections.

Guidelines recommend testing for calprotectin and lactoferrin in stool samples and C-reactive protein in the blood.

Crohn's disease and ulcerative colitis can affect food intake and lead to malabsorption of nutrients and intestinal bacterial overgrowth.

Cerebral organoids shed light on cells that generate the myelin cells that protect the axons of neuron. In multiple sclerosis, inflammatory processes attack the myelin of neurons in the brain and spinal cord.

Some people with multiple sclerosis follow dairy-free or plant-based diets that may be low on calcium and vitamin D.

The classes with the strongest association with inflammatory bowel disease were those typically used to treat GI infections, nitroimidazoles and fluoroquinolones.

The new law raises the age threshold for the onset of disabling conditions that make people eligible to have the savings accounts. The money in the accounts do not count toward the limits for Medicaid and the Supplemental Nutritional Assistance Program.

Research by Maria T. Abreu, M.D., and Jacob McCauley, Ph.D., should help fill a gap in the research of the genetics of inflammatory bowel disease, including ulcerative colitis.

A Swedish and a French company have treatments with novel mechanisms of action in late-stage development. Meanwhile, AbbVie, Janssen and Eli Lilly are vying to get the first interleukin-23 inhibitor for ulcerative colitis on the market.

Spanish researchers found that progression of multiple sclerosis that was independent of relapses of the disease was associated with worse long-term outcomes.

A study by Kaiser Permanente researchers found that the overall the risk of COVID-19-related hospitalization was low in vaccinated individuals with multiple sclerosis, regardless of whether participants had received Rituxan treatment. Still, the findings suggest that spacing out vaccination may offer added protection against COVID-19.